The Briefing: Skechers, TikTok, and Khaby Lame: Is Barrett Wissman Potentially Liable?
The LathamTECH Podcast — Trade Secrets: The New Litigation Battleground
Podcast: Williams Mullen's Trending Now - An IP Podcast - When AI Meets Art: Litigation and Settlement Trends Affecting Artists
The Briefing: Vetter v. Resnik: When Copyright Termination Goes Global
IP Goes Pop! S7 Ep 1- We’re #1! Intellectual Property Firsts
Why Won't the USPTO Register My Last Name? — No Infringement Intended Podcast
The Briefing: Kat Von D, Miles Davis, and the Possible Death of the Intrinsic Test?
2026 Trends to Watch: Regulation, Infrastructure and IP in Motion
'Desk Drawer Roundup': NIL Contract Fights, Eligibility Battles, and the CSC Participation Agreement — Highway to NIL Podcast
The Briefing: Part Two: CCPA’s New Rules on Risk Assessments and Cybersecurity Audits
The Briefing: Part One: CCPA’s New Rules on Automated Decision making Technology (ADMT)
We get AI for work™: New Efforts to Ensure a National AI Policy
The Briefing: Why Lady Gaga Beat a Trademark Injunction Over “Mayhem”
Beyond the Deals: Student-Athlete Identity, Development, and NIL With 42U's Stephen Bienko — Highway to NIL Podcast
The Privacy Insider Podcast Episode 22: The Data Privacy of the Dead & Critiquing the Digital Divine with Carl Öhman of Uppsala University
Why Does Everyone Say 'The Big Game' Instead of 'Super Bowl'? — No Infringement Intended Podcast
The Briefing: Top Gun Cleared for Takeoff: The Ninth Circuit Affirms Paramount’s Copyright Win
The Briefing: The 2026 Forecast: Resolving Some of the Entertainment Industry’s Open Legal Issues
The Briefing: 2025 IP Resolutions Start With a Review of IP Assets (Featured)
Wolf Greenfield Attorneys Review 2025 and Look Ahead to 2026
Businesses Should Assess All Parts Of Their Supply Chain To Determine Whether A Controlled Item Is Being Exported....more
If you are preparing to sell your business, there is one part of the process that often catches founders by surprise....more
AI has become a buzzword synonymous with transformation, revolution, and innovation. Some industries are closer to effectively implementing AI solutions than others, due to the nature of their work and the complexity of the...more
Adalimumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
On March 2, 2026, the U.S. Supreme Court denied the petition for a writ of certiorari in Thaler v. Perlmutter, No. 25-449, ending a multi-year effort to secure copyright protection for a work, “A Recent Entrance to Paradise,”...more
In a significant decision for the biotechnology sector, the Federal Circuit provided much needed clarity on the patent eligibility of genetically engineered compositions. The Federal Circuit held that the genetically...more
Rituximab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference product sponsors as well as...more
The rapid digitization of the built environment has transformed real estate from a traditionally asset-heavy industry into a veritable data-driven ecosystem. The technology driving this transformation is commonly referred to...more
In REGENXBIO v. Sarepta Therapeutics, the Federal Circuit recently held that a cell containing a non-naturally occurring recombinant nucleic acid molecule is not a product of nature and is patent‑eligible under 35 U.S.C. §...more
On February 20, 2026, the Federal Circuit held that patent claims directed to a cultured host cell are patent-eligible under 35 U.S.C. § 101—reversing a district court’s January 2024 decision granting summary judgment of...more
Insulin Glargine Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
Trastuzumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
On February 17, 2026, the Court dismissed Sandoz’s Complaint against Amgen in Case No. 2:25-cv-00218 (E.D. Va.) for failure to state a claim under FRCP 12(b)(6). ...more
In March 2026, the Office of the U.S. Trade Representative (“USTR”) released its 2025 Review of Notorious Markets for Counterfeiting and Piracy (the “Notorious Markets List” or “NML”). The report highlights prominent examples...more
On March 3, 2026, the U.S. Food and Drug Administration (FDA) announced the publication of its new draft guidance “New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers” ("NCIE...more
The Federal Circuit recently emphasized that patentees must distinguish between functional and ornamental features claimed in design patents or otherwise risk facing a narrowed construction of the patents’ claims....more
Thoughtful estate planning is essential for artists seeking to ensure the long‑term preservation, management, and presentation of their lifelong work....more
In Ingevity Corp. v. BASF Corp., the Federal Circuit affirmed a jury verdict finding that Ingevity Corp. (Ingevity) violated antitrust laws by tying licenses to its fuel‑vapor canister patent to purchases of its unpatented...more
On February 27, 2026, the U.S. Patent and Trademark Office and Antitrust Division of the U.S. Department of Justice filed a “Statement of Interest” in Collision Communications, Inc. v. Samsung Electronics Co., Ltd., a case...more
In Range Of Motion Products, LLC v. Armaid Company Inc., Appeal No. 23-2427, the Federal Circuit held that functional aspects of a design must be separated out when analyzing whether an ordinary observer would find two...more
On March 3, Janssen Biotech, Inc. and Janssen Sciences Ireland UC (collectively, “Janssen”) filed a BPCIA complaint in the U.S. District Court for the District of Delaware against Accord BioPharma, Inc. and Bio-Thera...more
As readers will be aware, at the end of 2025, the EU institutions agreed the text of the EU Pharma Package: the wholesale change to the pharmaceutical regime in the EU that has been debated for many years. The changes...more
The US Supreme Court has declined to consider the copyrightability of artwork generated purely autonomously by artificial intelligence, leaving in place the “human authorship requirement” for copyright protection. In this...more
The U.S. Supreme Court has declined to hear Dr. Stephen Thaler’s appeal seeking copyright protection for his AI‑generated artwork A Recent Entrance to Paradise. The decision allows to stand the long series of administrative...more